articleTop 1% cited
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2009 · Vol. 27(28) · pp. 4733–4740
Henry S. Friedman✉(Neurological Surgery)Michael D. Prados(Neurological Surgery)Patrick Y. Wen(Neurological Surgery)Tom Mikkelsen(Neurological Surgery)David Schiff(Neurological Surgery)Lauren E. Abrey(Neurological Surgery)W.K. Alfred Yung(Neurological Surgery)Nina A. Paleologos(Neurological Surgery)M. Kelly Nicholas(Neurological Surgery)Randy L. Jensen(Neurological Surgery)James J. Vredenburgh(Neurological Surgery)Jane Huang(Neurological Surgery)Maoxia Zheng(Neurological Surgery)Timothy F. Cloughesy(Neurological Surgery)
Abstract
Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma.
Glioma Diagnosis and TreatmentCancer Treatment and PharmacologyCancer, Hypoxia, and MetabolismMedicineBevacizumabIrinotecanGlioblastomaOncologyInternal medicineSurgeryChemotherapyCancerColorectal cancer
MeSH terms
BevacizumabIrinotecanAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCamptothecinDrug Administration ScheduleFemaleGlioblastomaHumansMaleMiddle AgedNeoplasm Recurrence, Local
Citations
2,431
FWCI
86.19
field-weighted impact
References
30
Percentile
100%
vs. same field & year
Citations per year
Cited by
Management of glioblastoma: State of the art and future directions
CA A Cancer Journal for Clinicians · 2020 · 1,989 citations
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Journal of Clinical Oncology · 2010 · 3,781 citations
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
CA A Cancer Journal for Clinicians · 2010 · 1,392 citations
The Microenvironmental Landscape of Brain Tumors
Cancer Cell · 2017 · 1,790 citations
Antibody therapy of cancer
Nature reviews. Cancer · 2012 · 2,121 citations
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Cancer Letters · 2016 · 648 citations
Immunotherapy for glioma: Current management and future application
Cancer Letters · 2020 · 765 citations
References
Response criteria for phase II studies of supratentorial malignant glioma.
Journal of Clinical Oncology · 1990 · 2,400 citations
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
British Journal of Cancer · 2000 · 935 citations
The biology of VEGF and its receptors
Nature Medicine · 2003 · 9,519 citations
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Clinical Cancer Research · 2007 · 1,074 citations
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
New England Journal of Medicine · 2005 · 21,276 citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2004 · 1,949 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
Related articles
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2009 · 2,431 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.